Login
Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

immixbio.com

What Do They Do?

Develops therapies made from patients’ modified immune cells for people with light-chain amyloidosis and other serious diseases.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Portfolio focus The older report described tissue-targeted drug programs for solid tumors and inflammation alongside a separate cell-therapy unit; the latest centers on CAR-T for AL amyloidosis and other serious diseases.

Who Do They Compete With?

Competes with Abbvie, Caelum Biosciences, Alexion, AstraZeneca, Janssen, and Johnson & Johnson

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support